^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DSP502

    i
    Other names: DSP502, DSP-FC 502, DSP 502, DSP FC 502, DSP-502, DSPFC502
    Associations

    News

    Trials
    Company:
    Kahr Medical
    Drug class:
    PD-L1 inhibitor, TIGIT inhibitor
    Related drugs:
    Associations

    News

    Trials
    3years
    DSP502 — A Novel Approach For Targeting TIGIT And PD1 Pathways For Cancer Immunotherapy (SITC 2021)
    Beyond targeting PVR and PDL1, DSP502 has the potential to additionally impact the TIGIT pathway through its effects on CD96 and DNAM1. DSP502 is currently in IND-enabling studies and CMC development.
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • GZMB (Granzyme B)
    |
    PD-L1 overexpression
    |
    DSP502